Skip to content

Abstract 14366: Not All Factor Xa Inhibitors Are Equal: Apixaban a Better Choice Than Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: Evidence from a Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Behind every atrial fibrillation diagnosis lies a fivefold increased stroke risk, leading to inclusion of anticoagulant therapy. Transition from Vitamin K antagonists to Direct Oral Anti Coagulants (DOACs) has revolutionized anticoagulation in non-valvular atrial fibrillation, increasing compliance and reducing morbidity/mortality. Real-world comparative effectiveness between apixaban and rivaroxaban remains incompletely defined. We aimed to bridge this clinical gap. Methods: We conducted a comprehensive literature search of PubMed/MEDLINE, Google Scholar, Cochrane Library, PLOS ONE, and ClinicalTrials.gov between January 2015 and December 2025. Eligible populations on Apixaban and Rivaroxaban were propensity matched. A Risk of Bias assessment was conducted using ROBINS-1 tool. Pre-specified outcomes included Ischemic Stroke incidence, Hemorrhagic stroke, and Bleeding risks (ICH, GI Bleeds, Other Bleeds). Statistical heterogeneity was evaluated using the I 2 statistic. Results: A total of 13 studies comprising 1,013,094 patients (apixaban: n = 537,030; rivaroxaban: n = 476,064) were included in the final analysis. Across 11 studies (n=967,367), apixaban was associated with significantly lower ischemic stroke risk compared to rivaroxaban (OR 0.85 [95% CI 0.82-0.87], p<0.00001), though substantial heterogeneity was noted (I 2 =98%). Among 4 studies (n=627,699), no statistically significant difference in hemorrhagic stroke was observed between apixaban and rivaroxaban (OR 0.97 [95% CI 0.88-1.07], p=0.55), with high heterogeneity (I 2 =97%). Across 12 studies, Apixaban also demonstrated significantly lower overall bleeding risk (n=1,013,094) compared to rivaroxaban (OR 0.61 [95% CI 0.60-0.63], p<0.00001; I 2 =89%). Discussion: Our study evaluating patients with non-valvular atrial fibrillation (NVAF) is one of the largest head-to-head analyses comparing apixaban versus rivaroxaban. The results favored apixaban in reducing overall ischemic stroke events, though no statistically significant difference was identified in hemorrhagic stroke events. This is likely due to apixaban's twice-daily dosing and lower plasma concentration variability compared to rivaroxaban's once-daily regimen, which produces more pro-hemorrhagic peak plasma levels. With no dedicated randomized controlled trial between apixaban and rivaroxaban in NVAF, this pooled real-world analysis represents indirect comparative evidence. Conclusion: Our analysis demonstrates that apixaban is associated with a lower incidence of ischemic stroke and lower bleeding risk, with comparable hemorrhagic stroke rates. In the absence of a large prospective clinical trial supporting this, our study would guide clinical decision-making. This hopefully paves the way for future RCTs.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.